To view this email as a web page, click here.

 
SLE Trend: Predictors of Mortality Risk Change in Lupus
Over the past 20 years, while the demographics of systemic lupus erythematosus (SLE) hospitalizations have not noticeably changed, the comorbidities that lead to hospitalizations and poor outcomes in SLE have changed.
Read more
 
Lupus Damage Builds Over Time
A new study assesses the accumulation of steroid-related damage in adults who were diagnosed with lupus as children. In this slideshow, we highlight the findings.
Read more
 
New Treatment Option for Behçet’s Disease
On Friday, the U.S. Food and Drug Administration approved apremilast (Otezla, Celgene) for the treatment of oral ulcers associated with Behçet’s disease, a rare, chronic, multisystem inflammatory condition that affects approximately five in 100,000 people in the U.S.
Read more
 
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.